Compare Rockwell Automation (ROK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs GeneDx Holdings Corp — how do they compare? Rockwell Automation trades at $435.77 (market cap $48.21B), while GeneDx Holdings Corp trades at $69.07 (market cap $2.02B). The key difference: Rockwell Automation is far larger — about 23.9× GeneDx Holdings Corp's market cap, and Rockwell Automation pays a 1.27% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rockwell Automation for 74 Days and GeneDx Holdings Corp for 19 Days on average.
| ROK | WGS | |
|---|---|---|
Market Cap | $48.21B | $2.02B |
Volume | 953,342 | 734,640 |
Sector | Industrials | Health |
52-Week High | $495.08 | $167.51 |
52-Week Low | $333.75 | $34.51 |
Typical Hold Time | 74 Days | 19 Days |
Enterprise Value | $51.34B | $2.05B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $439.01, down 0.65% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company maintains solid profitability with a 13.38% net income margin and 34.47% ROE, though valuation ratios like a P/E of 40.65 appear elevated. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and new robotic platforms, supporting positive sector momentum.
The outlook is cautiously optimistic, with a consensus price target of $489.89 implying ~12% upside, but high valuation and macroeconomic pressures pose risks. Earnings growth and automation demand are key catalysts, yet investors face volatility from competitive and economic headwinds.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
